BARDA awards Sanofi $43.2M for Zika vaccine

Sanofi (Euronext:SAN; NYSE:SNY) and its Sanofi Pasteur vaccines unit said HHS's Biomedical Advanced Research and Development Authority will grant Sanofi Pasteur $43.2 million to conduct a Phase II trial of a purified inactivated Zika vaccine.

In July, Sanofi Pasteur partnered with the Walter Reed Army Institute of Research to co-develop the vaccine. Walter Reed and the National Institute of Allergy and Infectious Diseases (NIAID) are conducting Phase I studies of the vaccine, after which Sanofi Pasteur is to take over development (see BioCentury Extra, July 6). ...